Document is current
Any future updates will be listed below
-
Authors
Muniyandi, Anbukkarasi
Martin, Matthew
Sishtla, Kamakshi
Motolani, Aishat
Sun, Mengyao
Jensen, Nathan R.
Qi, Xiaoping
Boulton, Michael E.
Prabhu, Lakshmi
Lu, Tao
Corson, Timothy W.
-
Funding
Funding for this research was provided by:
National Institute of General Medical Sciences (R01GM120156-01A1)
National Center for Advancing Translational Sciences (UL1TR002529)
Indiana Drug Discovery Alliance (2286233)
National Eye Institute (R01EY025641)
Cohen Endowment for Macular Degeneration Research
Research to Prevent Blindness (Challenge Grant)
- License Information
-
More Information
Article History
Received: 15 July 2022
Accepted: 16 January 2023
First Online: 31 January 2023
Competing interests
: A.Mu., M.M., K.S., A.Mo., M.S., T.L., and T.W.C. are named inventors on U.S. Patent Application Number: 18/061,219 related to this work<sup>86</sup>. PR5-LL-CM01 is protected by US Patent Award to T.L. and L.P.<sup>87</sup>. T.L. is the founder of EQon Pharmaceuticals, LLC, a company that owns the licensed patent rights for PR5-LL-CM01 from Indiana University. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
